Barclays Adjusts Price Target on DaVita to $224 From $218

Barclays has increased its price target for DaVita Inc. (DVA) to $224 from $218. This adjustment follows other analyst updates, with BofA raising its target to $170 and Deutsche Bank to $265, reflecting varied outlooks on the healthcare facilities and services provider. The article also notes recent earnings results for DaVita, including increased adjusted EPS and revenue for Q2 2026.